

Application No. 10/696,391  
Amendment dated July 24, 2006  
After Final Office Action of March 22, 2006

2

Docket No.: 47624CIP(71417)

**AMENDMENTS TO THE CLAIMS**

The below listing of claims will replace all prior versions, and listings, of claims in the application.

1-48. (Canceled)

49. (currently amended) A method for inducing new blood vessel growth in myocardial tissue of a mammal in need of such treatment comprising:

a) administering an effective amount of a solution comprising a nucleic acid encoding at least one angiogenic protein or an effective fragment thereof into the myocardial tissue; and

b) administering to the mammal an effective amount of at least one angiogenic factor or an effective fragment thereof, thereby inducing the new blood vessel growth in the myocardial tissue of the mammal, and increasing the frequency of endothelial progenitor cells (EPC) in the mammal; and

c) monitoring a cardiac function by echocardiography, ventricular end-diastolic dimension (LVEDD), end-systolic dimension (LVESD), fractional shortening (FS), wall motion score index (WMSI), electromechanical mapping with a NOGA-system, cardiac angiography or LV systolic pressure (LVSP).

50. (Currently amended) The method of claim 49, wherein the angiogenic factor protein is a vascular endothelial growth factor (VEGF) or an effective fragment thereof.

51. ((Original)) The method of claim 50, wherein the VEGF is VEGF-1 or VEGF165.

52. ((Original)) The method of claim 49, further comprising expressing the angiogenic protein or fragment in the myocardium.

Application No. 10/696,391  
Amendment dated July 24, 2006  
After Final Office Action of March 22, 2006

3

Docket No.: 47624CIP(71417)

53. (Canceled)

54. (Previously presented) The method of claim 49, wherein the increase in frequency of the EPC is at least about 20% as determined by a standard EPC isolation assay.

55. (Original) The method of claim 49, wherein the method further comprises increasing EPC differentiation in the mammal.

56. (Original) The method of claim 55, wherein the increase in EPC differentiation is at least about 20% as determined by a standard EPC culture assay or a standard hindlimb ischemia assay.

57. (Original) The method of claim 50, wherein the level of VEGF or VEGF fragment expression is sufficient to increase neovascularization by at least about 5% as determined by a standard in vivo micropocket assay.

58. (Previously presented) The method of claim 49, wherein the administered angiogenic factor is stem cell factor (SCF), colony stimulating factor (CSF) or a fragment thereof in an amount sufficient to increase EPC bone marrow derived EPC incorporation into foci.

59. (Original) The method of claim 58, wherein the EPC bone marrow derived EPC incorporation into foci is at least about 20% as determined by a standard rodent bone marrow (BM) transplantation model.

Application No. 10/696,391  
Amendment dated July 24, 2006  
After Final Office Action of March 22, 2006

4

Docket No.: 47624CIP(71417)

60. (Original) The method of claim 49, wherein the method further comprises administering at least one angiogenic protein or effective fragment thereof before or after administration of the nucleic acid to the mammal.

61. (Original) The method of claim 49, wherein the method further comprises administering to the mammal an anti-coagulant before, during, or after administration of the nucleic acid to the mammal.

62. (Original) The method of claim 61, wherein the anti-coagulant is one or more of urokinase, plasminogen activator, and heparin.

63. (Original) The method of claim 49, wherein the nucleic acid is directly injected with a catheter or stent.

64. (Original) The method of claim 49, wherein the nucleic acid is inserted into a cassette operably linked to a promoter.

65. (Original) The method of claim 49, wherein the myocardial tissue is ischemic or is associated with infarction or dysfunction.

66-67. (Canceled)

68. (Previously presented) The method of claim 49, wherein the angiogenic protein or factor is one of acidic fibroblast growth factor (aFGF), basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF-1), VEGF165, epidermal growth factor (EGF),

Application No. 10/696,391  
Amendment dated July 24, 2006  
After Final Office Action of March 22, 2006

5

Docket No.: 47624CIP(71417)

transforming growth factor  $\alpha$  and  $\beta$  (TGF- $\alpha$  and TGF- $\beta$ ), platelet-derived endothelial growth factor (PD-ECGF), platelet-derived growth factor (PDGF), tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), hepatocyte growth factor (HGF), insulin like growth factor (IGF), erythropoietin, colony stimulating factor (CSF), macrophage-CSF (M-CSF), granulocyte/macrophage CSF (GM-CSF), stem cell factor (SCF), angiopoietin-1 (Ang1), nitric oxide synthase (NOS); or a mutein or fragment thereof.